Close

REACH Co-Pay Assistance

A New Level of Financial Support for
Privately-insured STIVARGA® (regorafenib) Patients*

Up to $4,000 per prescription and up to $16,000
per year per patient for privately-insured patients

Information for Patients Information for Health Care Providers

*Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the co-payment support provided under this program, e.g., co-pay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payors of any benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law, taxed, or restricted. Patients enrolled in Bayer’s Patient Assistance Program are not eligible. Bayer and Onyx may determine eligibility, monitor participation, equitably distribute product and modify or discontinue any aspect of the REACH program at any time, including but not limited to this commercial co-pay assistance program.